News

ChondroGrid® takes center stage in a new randomized controlled trial involving 135 patients with knee osteoarthritis - featured image

Editorial Bioteck

16 November 2026

ChondroGrid® takes center stage in a new randomized controlled trial involving 135 patients with knee osteoarthritis

An interesting randomized study directly comparing ChondroGrid, PRP, and hyaluronic acid in the treatment of knee osteoarthritis has just been published in the scientific journal Future Science OA. The clinical trial was conducted by Prof. Raeissadat (Tehran, Iran) on 135 patients with Kellgren-Lawrence grade 2–3 knee osteoarthritis.


ChondroGrid® is an infiltrative device based on bovine low-molecular-weight hydrolyzed collagen that reinforces the extracellular matrix. Its action promotes pain reduction and the restoration of function in joints and in muscular, tendinous, and ligamentous structures, which are primarily composed of collagen.


At six months, ChondroGrid® demonstrated clinical results comparable to PRP and superior to hyaluronic acid across various functional and quality-of-life parameters, while also recording the highest level of overall satisfaction among patients at the final follow-up.

> Learn more by reading the full article!

Logo Bioteck Academy


Vicenza
Headquarter
via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italy
Tel. +39 0444 289366
Fax: +39 0444 285272


Contact us


Torino
Multi-function production center
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italy

Copyright © 2026 Bioteck S.p.A. - Privacy Policy - Cookie Policy